Assembly Biosciences
ASMB
106 hedge funds and large institutions have $483M invested in Assembly Biosciences in 2018 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 33 increasing their positions, 38 reducing their positions, and 25 closing their positions.
0.1% less ownership
Funds ownership: 7.09% → 6.99% (-0.1%)
6% less funds holding
Funds holding: 113 → 106 (-7)
13% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 38
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
29% less call options, than puts
Call options by funds: $238K | Put options by funds: $337K
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
40% less capital invested
Capital invested by funds: $801M → $483M (-$318M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$16.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$6.45M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.16M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$3.79M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
+$3.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$13M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$12.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.26M |
| 4 |
O
OrbiMed
New York
|
-$5.72M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.13M |
ASMB Hedge Fund Activity: Q4 2018 in Review
106 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q4 2018, worth a combined $483M — down 40% from $801M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ASMB and 18 opened new positions — a net loss of 7 holders — while 38 trimmed existing stakes and 33 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $16.6M. The largest seller was EcoR1 Capital, cutting an estimated $13M.
- 106 institutional investors held Assembly Biosciences (ASMB) as of Q4 2018, down from 113 in Q3 2018.
- Funds reported $483M of Assembly Biosciences stock for Q4 2018, down 40% quarter-over-quarter.
- 18 funds opened new Assembly Biosciences positions in Q4 2018 and 25 closed out, a net change of -7 holders.
- The largest Assembly Biosciences buyer in Q4 2018 was RTW Investments, an estimated $16.6M added.
- The largest Assembly Biosciences seller in Q4 2018 was EcoR1 Capital, an estimated $13M sold.
Based on aggregated 13F filings for Q4 2018.